In the PARAGON phase II study (Tang et al., 2019) anastrozole given for at least 6 months was associated with a clinical benefit rate of 61% in patients with recurrent ER- and/or PR-positive low-grade ovarian cancer or serous ovarian borderline tumors. Here, ESR1 is linked to ovarian cancer.